Worst May be Over for Hydroxychloroquine Market; How Industry Players Will Regain Growth Cycle Again

Hydroxychloroquine Market Latest Edition Published with Forecast to 2030
AMA Research, a global market research and consulting organization, have released a new study titled "Hydroxychloroquine market - Global outlook to 2030".
Industries constant focus on reducing the operational cost and increased attention on core business, and need to improve scalability are expected to shape the Global Hydroxychloroquine market to grow at a CAGR of %.

The End-users, such as Hospitals, is boosting the Hydroxychloroquine market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

The Distribution Channel, such as Hospital Pharmacy, is boosting the Hydroxychloroquine market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

According to Analyst at AMA Research, the Global Hydroxychloroquine market will experience significant growth during the forecast period due to potential opportunities lying in the market such as . Some of the important driving forces are “High Demand for COVID-19 Treatment from Highly Affected Regions such as the United States, Italy and Others, Demand for Prevention and Treatment of Malaria and Robust Increase in the Distribution Channels”.
 

Hydroxychloroquine is a derivative of chloroquine that has both antimalarial and anti-inflammatory activities. It is used to prevent or treat malaria caused by mosquito bites. It is treated malaria by killing the parasites that cause the disease. It is also used to treat certain auto-immune diseases such as lupus and rheumatoid arthritis. India manufactures 70% of the world's supply of hydroxychloroquine, according to Indian Pharmaceutical Alliance (IPA). United States Food and Drug Administration has identified Hydroxychloroquine as a possible treatment for COVID-19. The studies showed that it shortens the time to clinical recovery of COVID-19 patients. The study conducting in France enrolling 80 patients showed that Hydroxychloroquine alone or in combination with Azithromycin appeared to reduce virus levels quicker. India is a dominant manufacturer of hydroxychloroquine because it is an inexpensive drug used to treat malaria, rheumatoid arthritis and lupus. The country has a production capacity of 40 tonnes of hydroxychloroquine (HCQ) every month, implying 200 million tablets of 200 mg each. However, due to increased demand, India has increased the production of Hydroxychloroquine (HCQ) to 300 million tablets from 122.3 million tablets.

The report provides an in-depth analysis and forecast about the industry covering the following key features:
o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies
o Analyses the Global Hydroxychloroquine market by Type (Hydroxychloroquine 200 mg, Hydroxychloroquine 300 mg and Hydroxychloroquine 400 mg), by Application (Lupus Erythematosus, Rheumatoid Arthritis, COVID-19 and Others) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
o Analyzes the top 10 players in terms of market reach, business strategy, and business focus
o Provides stakeholders’ insights and key trends (current and future) of the market

Praveen Kumar

Head & Director of Sales